Audit: QRS - Arsenicum album for Health & Longevity
Audit conducted on 06/09/2026 08:49 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked across all populated spans: protocol values against ER lines 298–306, time-to-effect against ER line 350, monitoring targets against the ER biomarker table (ER lines 378–386), cadence against ER line 374, gates against ER lines 256–278. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “no reliable time-to-effect curve established”, “Claimed by homeopathic doctrine”, “No established target” all mirror the ER’s hedged wording. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retained at full strength; the Medium benefit remains “Reduced reported respiratory illness”, not demonstrated protection. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gate content is drawn only from Key Interactions & Contraindications; tiered items only from Expected Benefits / Potential Risks & Side Effects. No modifying-factor content migrated. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers or manufacturer brand names appear. “Ministry of Ayush advisory, 29 January 2020” is present in the ER for the same protocol (ER line 298). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | The only attribution is the Ministry of Ayush advisory, carried from the ER. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s detached, design-conscious framing of a contested intervention. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Thresholds, potencies and biomarker targets are given without exhortation. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No imperatives; the protocol cells describe published schedules rather than instruct. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “should”, “must”, or “recommended” in the document’s own voice. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Marker rows state target and rationale; cadence is stated descriptively. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to biomarker names, which are unavoidable in the Monitoring table. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every span is a condensed clause; no prose paragraphs outside At-A-Glance. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your”/”yourself” tokens. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal functional ranges (ALT under 20/17 U/L, GGT under 20 U/L) rather than conventional lab flags. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Speciated urinary arsenic testing and a nine-marker panel presume that willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Empty-stomach timing windows and a multi-point monitoring cadence exceed general-population expectations. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance separates self-reported illness from verified infection — the distinction that matters to a hard-endpoint audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “pellets”, “potencies”, “drug-induced liver injury”, “hypersensitivity reactions” used throughout; the plainer At-A-Glance wording is required by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate headings and table column headers are byte-identical to the template; the Medium/Low/Speculative tier labels are unchanged. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variables are present; the repeatable marker_#_* and qualitative_item_# patterns are expanded to 9 and 6 instances respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A token-level diff of the QRS against the template, with variable contents masked, shows no difference other than the repeated Monitoring rows and Qualitative list items. The website="evidence_review", website="audit" and website="full_review" spans are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the ER’s High benefit and High risk tiers carry explanatory text rather than an empty state, and items 12.5/13.5 govern their handling. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Fixed-remedy prophylaxis protocol”, “Trial dosing variant”, “Best time of day” and all seven Key Interaction labels reproduce the ER’s bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names and tier labels match the ER table and headings exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji code points occur in the file; the ER’s ⚠️ Conflicted markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | The template’s per-section budget is respected: three protocol cells, three time-to-effect cells, one line per benefit and risk tier, and single-clause gate items. No section was extended beyond the template’s structure. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or footer. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: arsenicum_album_2026-0906-0614_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0906-0837. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all ten keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Arsenicum album for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Arsenicum album for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/06/2026”, the MM/DD/YYYY form of 2026-0906. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block contains only the template’s title and subline; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all four Conclusion paragraphs: the dilution, the design split, the funding interest, and the concrete harms. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “sugar pellet plus ritual” (ER line 413), “no difference in verified infection” (ER line 415), “the supporting work came from the body promoting it” (ER line 415), “liver injury, one death” (ER line 417). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “where nobody knew who got what” replaces “double-blind”; “verified infection” replaces “laboratory-confirmed infection”. No acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No study names, years or enrollment figures appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No odds ratios, confidence intervals or protection percentages carried over from ER lines 148–150. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items trace to the “Populations who should avoid Arsenicum album” list at ER lines 270–278. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER avoid-population bullets are represented, one-to-one and in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> |
🟢 | Lines 552–560: seven discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationales stripped: “given the absence of any safety data and the fact that inorganic arsenic crosses the placenta” and “in whom the mass-distribution programs supplied the preparation without any safety study in children” are both removed. No dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Child-Pugh B or C staging, the ALT “above twice the upper limit” threshold, 13 µg/L blood arsenic, 35 µg/g creatinine urinary arsenic, the age-12 cut-off and the 12C (24X) potency floor are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section; thresholds are written out as “above 13 micrograms per liter” and similar. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies seven such populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention --> |
N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items trace to the interaction bullets at ER lines 256–268. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All seven ER interaction bullets are present; none duplicates a Contraindication entry. |
| 9.3 | Individual [caution_items] are formatted as <li></li> |
🟢 | Lines 568–581: seven discrete <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanism and mitigation text stripped throughout (“since no molecules of the source substance remain”, “Mitigation: an electrocardiogram before use”, “Practitioners advise separating them from dosing by 30 minutes”). No dash-trailing clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named drugs retained: amiodarone, sotalol, azithromycin, methotrexate, isoniazid, fluconazole, itraconazole; plus the 12C potency threshold and the 3 g daily acetaminophen threshold. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section; its parentheses hold only drug examples and glosses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies seven interactions, and the section is correspondingly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used --> |
N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the Therapeutic Protocol bullets at ER lines 298, 300 and 306. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The advisory prophylaxis schedule, the largest-dataset trial schedule, and dose timing — the three bullets that specify what is actually taken and when. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains twelve bullets, well above three, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry substantive content; the dosing values, the age cut-offs, and the 15-to-30-minute clearance window all reproduce ER wording. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The trial measurement interval, the chronic-indication claim and the acute-indication claim — the three distinct intervals given at ER line 350. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Reported respiratory illness (Medium) first, chronic indications (Low) second, acute indications (Speculative) third — matching the ER’s benefit tiering. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names three distinct time-to-effect aspects, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans carry substantive content; each sub-line records the ER’s caveat that no reliable time-to-effect curve exists. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at line 350, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every item reproduces an ER Expected Benefits sub-heading (ER lines 146, 154, 162–174). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 530–542. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; the adjusted odds ratio 0.337, the 80.22% protection figure and the “Net reading” commentary are all omitted. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content appears in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | Line 530: benefits_high carries style="display: none" with no content, matching the ER’s “No benefit reaches High” at line 142. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Every item reproduces an ER Potential Risks & Side Effects sub-heading (ER lines 202, 208, 216, 222, 230–238). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 593–606. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; the 38.9% mortality figure, the 22.5% aggravation rate and the hazard ratio 2.50 are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s parenthetical gloss on homeopathic aggravation and the Common Terminology Criteria grading are both dropped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | Line 593: risks_high carries style="display: none" with no content, matching the ER’s “No risk reaches High” at line 198. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All rows trace to the biomarker table in Monitoring Protocol & Defining Success (ER lines 376–386). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER table rows are present in ER order, with targets reproduced exactly (ALT under 20/17 U/L, AST under 25 U/L, bilirubin 0.3–1.0 mg/dL, GGT under 20 U/L, blood arsenic under 5 µg/L, urinary speciated arsenic under 10 µg/L or 15 µg/g creatinine, platelets 200–300 × 10⁹/L, eGFR above 90 mL/min/1.73 m², symptom profile score). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 735–738 reproduce the ER’s cadence at line 374: baseline draw, liver panel at 4 weeks for a one-week to one-month course, then 4 weeks, 3 months and every 6 to 12 months for continued use. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items trace to the qualitative marker list at ER lines 390–395. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Six of six carried over: sleep and anxious waking, daytime energy, gastrointestinal comfort, restlessness and anxiety, skin and nail changes, appetite and thirst pattern. |
Issues 06/09/2026 08:49
Pass rate 100.00%. No issues found.
Issues 06/09/2026 08:44
- 4.5 — Sheet overflows one A4 page: Rendered content runs roughly 1.8 A4 pages; no per-section condensation was applied to the gate items (lines 551–585), the nine monitoring “Why” cells (lines 632–733), the verbatim cadence paragraph (lines 738–741) or the At-A-Glance block (lines 433–437).
- 7.4 — Trial jargon in At-A-Glance: “under blinding” (line 434) is methodology jargon; the ER’s own Conclusion avoids the term and spells the concept out in plain words at line 415.
Fixes 06/09/2026 08:44
- 7.4 — Trial jargon removed from At-A-Glance: Replaced “under blinding” with the plain-language “where nobody knew who got what”, mirroring the ER Conclusion; the block remains within the 60-word limit.
- 4.5 — Decision gates condensed: Trimmed the seven Contraindications and seven Key Interactions (e.g. “Documented elevated whole-blood arsenic (above 13 micrograms per liter)” → “Elevated whole-blood arsenic (above 13 µg/L)”); all thresholds, severity classes and named example drugs are retained.
- 4.5 — Monitoring “Why” column condensed: Shortened all nine why-cells to compact phrases (e.g. “Earliest signal of liver-cell injury from arsenic or adulterants” → “Earliest signal of liver-cell injury”), cutting roughly one wrapped line per table row.
- 4.5 — Cadence and cell subtext tightened: Condensed the monitoring cadence paragraph, the protocol and time-to-effect sub-lines, and two qualitative items, without dropping any ER-sourced fact.